UNITAID to invest more than $140M to evaluate point-of-care HIV diagnostics, monitoring in Africa

International medicines financing mechanism UNITAID said on Monday it "will invest more than $140 million to evaluate point-of-care [PoC] HIV diagnostic and monitoring technology in seven African countries," PlusNews reports, adding, "New technology could help put more people living with HIV on treatment faster and improve care, UNITAID partners said at the International AIDS Conference in Washington, D.C." (7/25). "The investment ... is being committed to projects implemented by the Clinton Health Access Initiative (CHAI), UNICEF and Medecins Sans Frontieres (MSF) to increase access to affordable point-of-care HIV diagnostics adapted for use in resource-poor settings," aidsmap notes in a news story (Smart, 7/24).

"UNITAID's money -- part of a three-year grant -- will go towards field-testing new PoC technology to diagnose babies born to HIV-positive mums early, and monitor HIV viral loads (the amount of virus in the blood) and CD4 counts (which measure the immune system's strength)," PlusNews writes, adding, "Point-of-care (PoC) technology provides health workers with access to complicated test results at the clinic level, but can also change how patients use the health system -- not always for the better" (7/25). "UNITAID has published reports on its website describing the current HIV diagnostics market landscape, and aidsmap will publish further reports on the issue over the coming days," aidsmap notes (7/24).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sweden becomes first country to meet global HIV targets